[go: up one dir, main page]

CY1125141T1 - Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d - Google Patents

Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d

Info

Publication number
CY1125141T1
CY1125141T1 CY20221100310T CY221100310T CY1125141T1 CY 1125141 T1 CY1125141 T1 CY 1125141T1 CY 20221100310 T CY20221100310 T CY 20221100310T CY 221100310 T CY221100310 T CY 221100310T CY 1125141 T1 CY1125141 T1 CY 1125141T1
Authority
CY
Cyprus
Prior art keywords
modified
nkg2d
linkers
domains
introduction
Prior art date
Application number
CY20221100310T
Other languages
English (en)
Inventor
Daniel Steiger
Steven R. Williams
David W. Martin
Kyle LANDGRAF
Original Assignee
Xyphos Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xyphos Biosciences Inc. filed Critical Xyphos Biosciences Inc.
Publication of CY1125141T1 publication Critical patent/CY1125141T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αυτή η αίτηση σχετίζεται γενικά με την παραγωγή πολυπεπτιδίων που έχουν ειδικές ιδιότητες δέσμευσης αντιγόνου περιοχών Fv, για παράδειγμα, εισαγόμενα μεταβλητά θραύσματα αντισωμάτων, και τροποποιημένες περιοχές α1-α2 των συνδετών NKG2D.
CY20221100310T 2014-12-05 2022-04-29 Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d CY1125141T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088456P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
CY1125141T1 true CY1125141T1 (el) 2024-12-13

Family

ID=56092677

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100310T CY1125141T1 (el) 2014-12-05 2022-04-29 Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d

Country Status (16)

Country Link
US (2) US11453713B2 (el)
EP (3) EP4079747A1 (el)
JP (5) JP2017537617A (el)
AU (2) AU2015357578B2 (el)
CA (2) CA2963274C (el)
CY (1) CY1125141T1 (el)
DK (1) DK3227311T3 (el)
ES (1) ES2907467T3 (el)
HR (1) HRP20220531T1 (el)
HU (1) HUE058851T2 (el)
LT (1) LT3227311T (el)
PL (1) PL3227311T3 (el)
PT (1) PT3227311T (el)
RS (1) RS63149B1 (el)
SI (1) SI3227311T1 (el)
WO (1) WO2016090278A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2993354A1 (en) * 2015-08-04 2017-02-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
AU2016410294A1 (en) * 2016-06-24 2019-01-03 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
CA3053010A1 (en) * 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
CL2017003503A1 (es) * 2017-12-29 2018-06-01 Univ Chile Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).
FI3749346T3 (fi) 2018-02-08 2024-09-04 Dragonfly Therapeutics Inc Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
KR20200132875A (ko) 2018-02-20 2020-11-25 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
CN112074532B (zh) 2018-03-27 2025-02-28 修普霍斯生物科学有限公司 结合非天然NKG2D受体的非天然NKG2D配体的修饰的α1-α2结构域
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP2022506540A (ja) * 2018-11-05 2022-01-17 サイフォス、バイオサイエンシズ、インコーポレイテッド 挿着されている細胞に直接シグナル伝達しない非天然ｎｋｇ２ｄ受容体
WO2020172189A1 (en) * 2019-02-18 2020-08-27 Courier Therapeutics, Inc. BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
WO2021226193A1 (en) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
KR20240107093A (ko) 2021-08-05 2024-07-08 고 테라퓨틱스, 인크. 항-글리코-muc4 항체 및 그의 용도
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
US20250066498A1 (en) 2021-09-03 2025-02-27 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
WO2024167875A1 (en) 2023-02-07 2024-08-15 Xyphos Biosciences Inc. Chimeric antigen receptor and antibody-nkg2d ligand domain fusion protein
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP1037991B1 (en) * 1997-12-17 2005-09-28 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
CA2628253A1 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
WO2008083493A1 (en) * 2007-01-10 2008-07-17 University Of Saskatchewan Stabilization of cyclic peptide structures
US8796420B2 (en) * 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
WO2012091756A1 (en) * 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
RU2444570C1 (ru) 2010-06-23 2012-03-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения и социального развития Российской Федерации Способ получения рекомбинантной вакцины
JP6018079B2 (ja) * 2010-12-30 2016-11-02 アビッドバイオティクス コーポレイション 非天然ｍｉｃタンパク質
TWI408370B (zh) * 2011-05-19 2013-09-11 Univ Chang Gung 胰臟癌之血清生物檢測標誌及其應用
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
RU2656183C2 (ru) * 2012-02-07 2018-05-31 Иннейт Фарма Связывающие mica агенты
US11117969B2 (en) * 2014-12-05 2021-09-14 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
CA2993354A1 (en) * 2015-08-04 2017-02-09 Avidbiotics Corp. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
CR20180509A (es) * 2016-05-02 2019-02-15 Hoffmann La Roche Contorsbody - un ligante de diana monocatenario

Also Published As

Publication number Publication date
SI3227311T1 (sl) 2022-04-29
WO2016090278A2 (en) 2016-06-09
CA3204990A1 (en) 2016-06-09
US11453713B2 (en) 2022-09-27
US20230002475A1 (en) 2023-01-05
JP2020114238A (ja) 2020-07-30
LT3227311T (lt) 2022-02-25
EP4079747A1 (en) 2022-10-26
CA2963274A1 (en) 2016-06-09
PT3227311T (pt) 2022-02-23
JP7132967B2 (ja) 2022-09-07
US20160159882A1 (en) 2016-06-09
DK3227311T3 (da) 2022-03-07
ES2907467T3 (es) 2022-04-25
AU2018223040B2 (en) 2020-04-30
JP7457558B2 (ja) 2024-03-28
EP3227311A4 (en) 2018-08-01
EP4043474A1 (en) 2022-08-17
HRP20220531T1 (hr) 2022-06-10
AU2018223040A1 (en) 2018-09-20
CA2963274C (en) 2024-01-30
AU2015357578B2 (en) 2018-11-08
JP2020114239A (ja) 2020-07-30
HUE058851T2 (hu) 2022-09-28
JP2022093353A (ja) 2022-06-23
WO2016090278A3 (en) 2016-07-28
EP3227311B1 (en) 2022-02-02
JP7083862B2 (ja) 2022-06-13
JP2020114854A (ja) 2020-07-30
RS63149B1 (sr) 2022-05-31
PL3227311T3 (pl) 2022-05-16
EP3227311A2 (en) 2017-10-11
JP2017537617A (ja) 2017-12-21
AU2015357578A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
CY1125141T1 (el) Εισαγωγη μεταβλητων θραυσματων αντισωματων και τροποποιημενοι τομεις α1-α2 των συνδετων nkg2d
CY1124691T1 (el) Διειδικα αντισωματα ειδικα για pd1 και τιμ3
EP4400517A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands, and non-natural nkg2d ligands that bind non-natural nkg2d receptors
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
PH12019502282A1 (en) Bispecific antibodies specifically binding to pd1 and lag3
CY1124108T1 (el) Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
BR112018010891A2 (pt) anticorpos e fragmentos de anticorpos para a conjugação específica do sítio
ZA201901066B (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
PH12017500890A1 (en) Antibody drug conjugates
MA49034B1 (fr) Anticorps anti-lag3
HUE050556T2 (hu) Anti-BCMA ellenanyagok, BCMA-t és CD3-at kötõ bispecifikus antigénkötõ molekulák és ezek alkalmazásai
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2021009275A (es) Moleculas de union especificas.
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2016012273A (es) Proteinas de union al antigeno vl que presentan diferentes caracteristicas de union.
WO2017222556A3 (en) Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
EA202090617A1 (ru) Варианты антител
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra